About Cytori Therapeutics (NASDAQ:CYTX)
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
Industry, Sector and Symbol
Trailing P/E Ratio-0.363949256403995
Forward P/E Ratio-1.74
Sales & Book Value
Annual Sales$2.69 million
Price / Sales6.96
Price / CashN/A
Book Value$0.22 per share
Price / Book1.42
Return on Equity-210.47%
Return on Assets-68.94%
Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions
What is Cytori Therapeutics' stock symbol?
Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."
When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?
Cytori Therapeutics shares reverse split on the morning of Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.
How were Cytori Therapeutics' earnings last quarter?
Cytori Therapeutics Inc (NASDAQ:CYTX) posted its earnings results on Thursday, March, 8th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The biotechnology company earned $1.50 million during the quarter, compared to analysts' expectations of $2 million. Cytori Therapeutics had a negative return on equity of 210.47% and a negative net margin of 418.36%. View Cytori Therapeutics' Earnings History.
When will Cytori Therapeutics make its next earnings announcement?
Where is Cytori Therapeutics' stock going? Where will Cytori Therapeutics' stock price be in 2018?
3 Wall Street analysts have issued 1-year price objectives for Cytori Therapeutics' stock. Their predictions range from $1.65 to $2.30. On average, they expect Cytori Therapeutics' stock price to reach $1.98 in the next year. View Analyst Ratings for Cytori Therapeutics.
What are Wall Street analysts saying about Cytori Therapeutics stock?
Here are some recent quotes from research analysts about Cytori Therapeutics stock:
- 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (3/8/2018)
- 2. Maxim Group analysts commented, "Cytori presented data in Ovarian Cancer at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting demonstrating bioequivalence of ATI-0918, generic liposomal formulation of doxorubicin, to J&Js CAELYX (branded EU product). We expect Cytori to file for approval in Europe in 2H18 and the company to partner ATI-0918 for commercialization. We profile the opportunity for liposomal doxorubicin, which was acquired with the acquisition of Azaya earlier in 2017, in the attachment below." (11/13/2017)
Who are some of Cytori Therapeutics' key competitors?
Some companies that are related to Cytori Therapeutics include Eleven Biotherapeutics (EBIO), Cleveland BioLabs (CBLI), Chiasma (CHMA), Capnia (SLNO), Vical (VICL), Zosano Pharma (ZSAN), Lipocine (LPCN), Evoke Pharma (EVOK), OvaScience (OVAS), Pernix Therapeutics (PTX), Kitov Pharma (KTOV), Concordia International (CXRX), AEterna Zentaris (AEZS), Innovus Pharmaceuticals (INNV), IntelliPharmaCeutics Intl (IPCI), Tonix Pharmaceuticals (TNXP), Neuralstem (CUR) and Regenerx Biopharmaceuticals (RGRX).
Who are Cytori Therapeutics' key executives?
Cytori Therapeutics' management team includes the folowing people:
- Richard James Hawkins, Chairman of the Board (Age 68)
- Marc H. Hedrick M.D., President, Chief Executive Officer, Director (Age 52)
- Tiago Girao, Chief Financial Officer, Chief Accounting Officer, Vice President - Finance (Age 35)
- Seijiro N. Shirahama, President , Asia Pacific (Age 60)
- John David Harris, Vice President, General Manager - Cell Therapy
- Jeremy Bragg Hayden, Vice President - Business Development, General Counsel
- Mark Marino M.D., Chief Medical Officer
- Gregg A. Lapointe, Director
- Gary A. Lyons, Independent Director (Age 66)
- Ronald A. Martell, Independent Director (Age 54)
Has Cytori Therapeutics been receiving favorable news coverage?
News articles about CYTX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytori Therapeutics earned a media sentiment score of 0.19 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Cytori Therapeutics' major shareholders?
Cytori Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (6.08%). Company insiders that own Cytori Therapeutics stock include Ag Postfinance, Bank Sa Swissquote, Gail K Naughton and John David Harris. View Institutional Ownership Trends for Cytori Therapeutics.
Which major investors are buying Cytori Therapeutics stock?
CYTX stock was bought by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. Company insiders that have bought Cytori Therapeutics stock in the last two years include Gail K Naughton and John David Harris. View Insider Buying and Selling for Cytori Therapeutics.
How do I buy shares of Cytori Therapeutics?
Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytori Therapeutics' stock price today?
One share of CYTX stock can currently be purchased for approximately $0.31.
How big of a company is Cytori Therapeutics?
Cytori Therapeutics has a market capitalization of $19.12 million and generates $2.69 million in revenue each year. The biotechnology company earns $-22,680,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Cytori Therapeutics employs 37 workers across the globe.
How can I contact Cytori Therapeutics?
Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]
MarketBeat Community Rating for Cytori Therapeutics (CYTX)MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cytori Therapeutics (NASDAQ:CYTX) Earnings History and Estimates Chart
Cytori Therapeutics (NASDAQ CYTX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2018|| || || || || || || || |
|3/8/2018||Q4 2017||($0.09)||($0.10)||$2.00 million||$1.50 million||View||Listen|
|11/9/2017||Q3 17||($0.16)||($0.14)||$2.04 million||$1.77 million||View||N/A|
|8/10/2017||Q2 2017||($0.16)||($0.18)||$2.23 million||$0.90 million||View||N/A|
|5/11/2017||Q1 2017||($0.31)||($0.26)||$2.32 million||$0.60 million||View||N/A|
|3/23/2017||Q4 16||($0.23)||($0.24)||$3.36 million||$1.50 million||View||N/A|
|11/9/2016||Q316||($0.24)||($0.26)||$2.85 million||$2.61 million||View||Listen|
|8/4/2016||Q216||($0.39)||($0.43)||$2.50 million||$1.10 million||View||N/A|
|5/10/2016||Q1||($0.03)||($0.41)||$2.05 million||$2.90 million||View||Listen|
|3/3/2016||Q4||($0.04)||($0.03)||$2.90 million||$1.56 million||View||N/A|
|11/5/2015||Q315||($0.06)||($0.04)||$5.27 million||$2.48 million||View||N/A|
|8/6/2015||Q215||($0.03)||($0.03)||$2.50 million||$1.60 million||View||N/A|
|5/11/2015||Q115||($0.07)||($0.07)||$2.44 million||$0.90 million||View||Listen|
|3/12/2015||Q4 14||($0.08)||($0.08)||$3.10 million||$2.47 million||View||N/A|
|11/6/2014||Q3 2014||($0.09)||($0.12)||$4.31 million||$1.10 million||View||N/A|
|8/11/2014||Q2 2014||($0.11)||($0.15)||$2.76 million||$0.94 million||View||N/A|
|5/12/2014||Q114||($0.14)||($0.14)||$2.87 million||$1.03 million||View||N/A|
|3/12/2014||Q413||($0.12)||($0.14)||$4.37 million||$2.71 million||View||N/A|
|11/7/2013||Q313||($0.11)||($0.08)||$3.17 million||$8.70 million||View||N/A|
|8/8/2013||Q2 2013||($0.13)||($0.16)||$2.88 million||$6.00 million||View||N/A|
|5/9/2013||Q1 2013||($0.16)||($0.11)||$3.24 million||$1.39 million||View||N/A|
|11/8/2012||Q312||($0.15)||($0.19)||$2.25 million||$1.31 million||View||N/A|
Cytori Therapeutics (NASDAQ:CYTX) Earnings Estimates
2018 EPS Consensus Estimate: ($0.20)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Cytori Therapeutics (NASDAQ CYTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 10.57%
Cytori Therapeutics (NASDAQ CYTX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/13/2018||Ag Postfinance||Major Shareholder||Sell||286,982||$0.31||$88,964.42||5,118,627|| |
|2/9/2018||Ag Postfinance||Major Shareholder||Sell||236,155||$0.34||$80,292.70||5,311,451|| |
|1/11/2018||Bank Sa Swissquote||Major Shareholder||Sell||72,630||$0.34||$24,694.20||5,496,655|| |
|1/9/2018||Bank Sa Swissquote||Major Shareholder||Sell||100,000||$0.38||$38,000.00||5,496,655|| |
|8/10/2016||John David Harris||VP||Buy||2,500||$2.03||$5,075.00||7,000|| |
|6/14/2016||Gail K Naughton||Director||Buy||1,000||$2.10||$2,100.00||2,400|| |
|5/13/2016||John David Harris||VP||Buy||2,000||$2.71||$5,420.00||2,000|| |
|3/9/2016||David Rickey||Director||Buy||150,000||$0.19||$28,500.00|| |
|9/3/2015||Tommy G Thompson||Director||Buy||25,449||$0.37||$9,416.13|| |
|9/2/2015||Jeremy B Hayden||VP||Buy||8,200||$0.36||$2,952.00||26,200|| |
|8/28/2015||David Rickey||Director||Buy||56,000||$0.31||$17,360.00|| |
|8/28/2015||Marc H Hedrick||CEO||Buy||11,200||$0.31||$3,472.00||504,611|| |
|8/27/2015||David Rickey||Director||Buy||75,000||$0.31||$23,250.00|| |
|8/21/2015||David Rickey||Director||Buy||50,000||$0.38||$19,000.00|| |
|8/21/2015||Marc H Hedrick||CEO||Buy||5,000||$0.38||$1,900.00||504,611|| |
|8/20/2015||Marc H Hedrick||CEO||Buy||10,000||$0.40||$4,000.00||504,611|| |
|8/19/2015||David Rickey||Director||Buy||48,600||$0.39||$18,954.00|| |
|8/19/2015||Steven Kesten||VP||Buy||6,000||$0.39||$2,340.00||2,201|| |
|8/18/2015||David Rickey||Director||Buy||51,400||$0.39||$20,046.00|| |
|8/18/2015||Marc H Hedrick||CEO||Buy||10,000||$0.39||$3,900.00||504,611|| |
|8/18/2015||Tiago Girao||CFO||Buy||25,000||$0.39||$9,750.00||88,000|| |
|11/13/2014||David Rickey||Director||Buy||20,000||$0.47||$9,400.00|| |
|11/12/2014||David Rickey||Director||Buy||200,000||$0.39||$78,000.00|| |
|11/12/2014||Tiago Girao||CFO||Buy||60,000||$0.39||$23,400.00|| |
|11/11/2014||Tiago Girao||CFO||Buy||15,889||$0.39||$6,196.71|| |
|6/5/2014||David Rickey||Director||Buy||30,000||$2.34||$70,200.00|| |
|9/12/2013||David Rickey||Director||Buy||7,100||$2.55||$18,105.00|| |
|9/11/2013||David Rickey||Director||Buy||2,000||$2.58||$5,160.00|| |
|9/9/2013||David Rickey||Director||Buy||5,000||$2.31||$11,550.00|| |
|9/5/2013||David Rickey||Director||Buy||2,000||$2.24||$4,480.00|| |
|9/3/2013||David Rickey||Director||Buy||7,000||$2.14||$14,980.00|| |
|8/30/2013||Tommy G Thompson||Director||Buy||5,000||$2.14||$10,700.00|| |
|12/19/2012||Lloyd H Dean||Director||Buy||25,000||$2.85||$71,250.00|| |
|12/19/2012||Marc H Hedrick||President||Buy||10,000||$2.85||$28,500.00|| |
Cytori Therapeutics (NASDAQ CYTX) News Headlines
|Edited Transcript of CYTX earnings conference call or presentation 8-Mar-18 10:30pm GMT|
finance.yahoo.com - March 18 at 6:23 PM
|Cytori Therapeutics (CYTX) PT Set at $2.00 by Maxim Group|
www.americanbankingnews.com - March 10 at 5:10 PM
|Cytori Therapeutics (CYTX) Issues Earnings Results|
www.americanbankingnews.com - March 10 at 9:56 AM
|Cytori Therapeutics (CYTX) Stock Rating Upgraded by B. Riley|
www.americanbankingnews.com - March 9 at 8:33 PM
|Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha|
seekingalpha.com - March 9 at 8:20 AM
|Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results - GlobeNewswire (press release)|
globenewswire.com - March 9 at 8:20 AM
|Cytori reports 4Q loss|
finance.yahoo.com - March 9 at 8:20 AM
|Cytori Therapeutics (CYTX) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - March 8 at 8:48 PM
|Want To Invest In Cytori Therapeutics Inc (NASDAQ:CYTX)? Here’s How It Performed Lately|
finance.yahoo.com - March 8 at 6:44 PM
|Cytori Therapeutics Q4 Earnings Preview|
finance.yahoo.com - March 8 at 6:44 PM
|Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results|
finance.yahoo.com - March 8 at 6:44 PM
|FY2017 EPS Estimates for Cytori Therapeutics Inc Cut by B. Riley (CYTX)|
www.americanbankingnews.com - March 8 at 7:54 AM
|Laidlaw Resumes Cytori Therapeutics, Inc. (CYTX) at Buy - StreetInsider.com|
www.streetinsider.com - February 24 at 8:15 AM
|Cytori Therapeutics' (CYTX) "Buy" Rating Reiterated at Laidlaw|
www.americanbankingnews.com - February 22 at 9:42 PM
|Cytori to Webcast Fourth Quarter Financial Results on March 8th|
finance.yahoo.com - February 22 at 5:37 PM
|Financial Comparison: Align Technology (ALGN) & Cytori Therapeutics (CYTX)|
www.americanbankingnews.com - February 22 at 11:50 AM
|Cytori Scleroderma Trial Data Presented at Systemic Sclerosis World Congress|
finance.yahoo.com - February 15 at 9:29 AM
|Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $88,964.42 in Stock|
www.americanbankingnews.com - February 14 at 6:32 PM
|Cytori Therapeutics (CYTX) Lowered to "Sell" at Zacks Investment Research|
www.americanbankingnews.com - February 13 at 9:44 PM
|Cytori Therapeutics (CYTX) Given a $4.00 Price Target at Maxim Group|
www.americanbankingnews.com - February 13 at 1:28 PM
|Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $80,292.70 in Stock|
www.americanbankingnews.com - February 12 at 6:46 PM
|Cytori Therapeutics Announces Inducement Grants for New Employees|
finance.yahoo.com - February 10 at 9:43 AM
|Comparing Antares Pharma (ATRS) and Cytori Therapeutics (CYTX)|
www.americanbankingnews.com - February 9 at 3:04 PM
|Cytori Therapeutics (CYTX) Given a $5.00 Price Target at Maxim Group|
www.americanbankingnews.com - January 22 at 6:36 PM
|Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $38,000.00 in Stock|
www.americanbankingnews.com - January 11 at 12:32 PM
|Bank Sa Swissquote Sells 72,630 Shares of Cytori Therapeutics Inc (CYTX) Stock|
www.americanbankingnews.com - January 11 at 12:32 PM
|Here’s Why Cytori Therapeutics Inc (CYTX) Shares Skyrocketed Today|
finance.yahoo.com - January 6 at 9:35 AM
|Cytori Therapeutics jumps as Maxim sees it as takeover candidate|
seekingalpha.com - January 5 at 7:02 PM
|Cytori Therapeutics (CYTX) Given a $5.00 Price Target by Maxim Group Analysts|
www.americanbankingnews.com - January 5 at 6:28 PM
|Cytori Therapeutics Inc (CYTX) Short Interest Down 35.6% in December|
www.americanbankingnews.com - January 1 at 1:16 AM
|ETFs with exposure to Cytori Therapeutics, Inc. : December 18, 2017|
finance.yahoo.com - December 18 at 5:14 PM
|Financial Analysis: Haemonetics (HAE) & Cytori Therapeutics (CYTX)|
www.americanbankingnews.com - December 16 at 1:34 PM
|Head-To-Head Analysis: Cytori Therapeutics (CYTX) and Symmetry Medical (SMA)|
www.americanbankingnews.com - December 12 at 3:24 AM
|ETFs with exposure to Cytori Therapeutics, Inc. : December 8, 2017|
finance.yahoo.com - December 8 at 5:10 PM
|Cytori Therapeutics (CYTX) & Inogen (INGN) Critical Comparison|
www.americanbankingnews.com - December 5 at 1:38 AM
|Cytori Therapeutics Inc’s (CYTX) Earnings Declined 36.4%, But How Did It Fare Against The Industry?|
finance.yahoo.com - November 30 at 5:12 PM
|Cytori Closes Rights Offering for Gross Proceeds of $10 Million - GlobeNewswire (press release)|
globenewswire.com - November 29 at 5:35 PM
|Cytori Closes Rights Offering for Gross Proceeds of $10 Million|
finance.yahoo.com - November 28 at 5:16 PM
|ETFs with exposure to Cytori Therapeutics, Inc. : November 27, 2017|
finance.yahoo.com - November 27 at 6:06 PM
|Analyzing VWR (VWR) and Cytori Therapeutics (CYTX)|
www.americanbankingnews.com - November 26 at 3:48 AM
|Cytori Announces Expiration of Oversubscribed Rights Offering - GlobeNewswire (press release)|
globenewswire.com - November 24 at 4:06 PM
|Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017|
finance.yahoo.com - November 21 at 5:59 PM
|Cytori Therapeutics (CYTX) Announces Reduction in Fibrosis ... - StreetInsider.com|
www.streetinsider.com - November 21 at 4:47 AM
|Cytori Reports Reduction in Fibrosis Parameters in Scar Study|
finance.yahoo.com - November 20 at 6:43 PM
|Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS - GlobeNewswire (press release)|
globenewswire.com - November 16 at 6:18 PM
|Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21|
finance.yahoo.com - November 16 at 1:17 PM
|Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS|
finance.yahoo.com - November 16 at 1:17 PM
|Analyzing Cytori Therapeutics (CYTX) and Its Competitors|
www.americanbankingnews.com - November 16 at 11:38 AM
|Maxim Group Analysts Give Cytori Therapeutics Inc (CYTX) a $5.00 Price Target|
www.americanbankingnews.com - November 13 at 5:12 PM
|Cytori Announces New U.S. Investigator Trial for Hip Osteonecrosis|
finance.yahoo.com - November 13 at 12:26 PM
Cytori Therapeutics (NASDAQ:CYTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cytori Therapeutics (NASDAQ:CYTX) Income Statement, Balance Sheet and Cash Flow Statement
Cytori Therapeutics (NASDAQ CYTX) Stock Chart for Friday, March, 23, 2018